TLC - Taiwan Liposome Company, Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.82
-0.18 (-3.00%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close6.00
Open6.00
Bid4.80 x 800
Ask10.00 x 800
Day's Range5.81 - 6.00
52 Week Range5.02 - 11.00
Volume550
Avg. Volume4,695
Market Cap191.186M
Beta (3Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.51
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    TLC to Present at Upcoming Conferences

    SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, April 22, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and.

  • GlobeNewswire9 days ago

    TLC Announces Positive End-of-Phase II Meeting with FDA for TLC599 in Knee Osteoarthritis

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the successful completion of its End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) on receiving guidance, and discussing the clinical and regulatory pathway for a potential U.S. approval of TLC599, a BioSeizer® liposomal formulation of dexamethasone sodium phosphate for the treatment of knee osteoarthritis. In agreement with the FDA, the Company believes its proposed overall design of a single global pivotal Phase III trial will be sufficient to support a New Drug Application (NDA) submission.

  • GlobeNewswire16 days ago

    TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the earlier-than-scheduled full enrollment in Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy. TLC590 is a proprietary BioSeizer® liposomal formulation of ropivacaine engineered to provide fast and sustained postsurgical pain relief for up to 96 hours. Results from Part 1 of the Phase II clinical trial are expected in mid-2019.

  • GlobeNewswire23 days ago

    TLC Reports Fourth Quarter and Full Year 2018 Financial Results and Business Update

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 01, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

  • GlobeNewswirelast month

    TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019

    SOUTH SAN FRANCISCO, Calif. and TAIPAI, Taiwan, March 25, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

  • GlobeNewswirelast month

    TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced that the first patient has been dosed a Phase II clinical trial for TLC590 following bunionectomy. TLC590 is a proprietary BioSeizer™ liposomal formulation of ropivacaine engineered to provide fast and sustained postsurgical pain relief for up to 96 hours, as recently demonstrated in a Phase I/II clinical trial. The Phase II, randomized, double-blind, comparator- and placebo-controlled clinical trial will evaluate the safety, pharmacokinetics, and efficacy of TLC590 compared with ropivacaine and placebo via a single infiltrative local administration in approximately 200 patients following bunionectomy across five sites in the US.

  • GlobeNewswirelast month

    TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today reported positive top-line results from the first in human Phase I/II clinical trial of TLC590, a proprietary BioSeizer™ sustained release formulation of ropivacaine, for postsurgical pain management. This randomized, double-blind, active-controlled, dose-escalation study evaluated the safety and tolerability of a single administration of TLC590 at four doses (190mg, 380mg, 475mg and 570mg) compared to a standard dose of ropivacaine (150mg, dose strength equivalent to 90mg bupivacaine) in 64 adult patients following inguinal hernia repair surgery.

  • GlobeNewswire2 months ago

    TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China

    Taiwan Liposome Company, Ltd. (“TLC”)(Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, and 3SBio Inc. ("3SBio")(1530.HK), a leading Chinese biopharmaceutical company specializing in oncology, nephrology, auto immune diseases, metabolic disorders and dermatology, today announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC’s proprietary NanoX™ technology platform. Under this alliance, TLC and 3SBio will cooperate to obtain regulatory approvals in mainland China, TLC will utilize its commercial-scale manufacturing capabilities to supply the two liposome products for 3SBio to commercialize in mainland China.

  • GlobeNewswire3 months ago

    TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer

    Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the appointment of George Spencer-Green, MD, MS, as TLC’s new Chief Medical Officer. With more than three decades of clinical medicine and drug development experience, Dr. Spencer-Green will serve as a member of the TLC Management Team and guide the company in its clinical and regulatory activities.

  • GlobeNewswire3 months ago

    EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma

    Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for TLC178 for the treatment of soft tissue sarcoma. Soft tissue sarcomas are cancers of the body's connective or supportive tissues, such as cartilage, fat, muscle, fibrous tissue, and blood vessels.

  • GlobeNewswire4 months ago

    TLC Announces Phase I/II Full Enrollment in Hernia Repair Surgery and Phase II Initiation in Bunionectomy of TLC590 for Postsurgical Pain

    Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced the full enrollment of TLC590’s Phase I/II clinical trial in patients following inguinal hernia repair surgery, as well as a protocol submission for the initiation of TLC590’s Phase II clinical trial in patients following bunionectomy. “We are quite pleased with the speed at which the Phase I/II trial has progressed,” noted TLC President George Yeh. “As a result of our prompt enrollment and dosing of all patients, we expect topline data on TLC590 in inguinal hernia repair surgery, a type of soft tissue surgery, in the first quarter of 2019.

  • GlobeNewswire5 months ago

    TLC to Attend Goldman Sachs Asia Pacific Healthcare Forum 2018

    TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Nov. 25, 2018 -- Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company.

  • GlobeNewswire5 months ago

    TLC Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq

    TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Nov. 21, 2018 -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to.